Codiagnostics, Inc. (CODX): ANSOFF Matrix Analysis [Jan-2025 Mis à jour]

Dans le paysage rapide des technologies de diagnostic, Co-Diagnostics, Inc. (CODX) est à l'avant-garde de l'innovation stratégique, trace un cours audacieux à travers le terrain complexe du diagnostic moléculaire. En tirant parti d'une matrice ANSOff complète, la société est prête à transformer sa présence sur le marché, repoussant les limites des tests cliniques, de l'expansion internationale, du développement technologique et de la diversification stratégique. Des tests Covid-19 de pointe aux plates-formes de diagnostic multiplex pionnières, CODX ne s'adapte pas seulement à l'écosystème des soins de santé - il le remodeance activement avec des stratégies calculées et avant-gardistes qui promettent de redéfinir la médecine de précision et les capacités de diagnostic.

Codiagnostics, Inc. (CODX) - Matrice Ansoff: pénétration du marché

Développez la force de vente directe ciblant les laboratoires cliniques et les prestataires de soins de santé

Depuis le quatrième trimestre 2022, les codiagnostics ont signalé une équipe de vente de 37 professionnels dévoués axés sur les segments du marché clinique et de la santé. Le chiffre d'affaires direct de la société a atteint 18,3 millions de dollars en 2022, avec une augmentation de 22% de la productivité des forces de vente par rapport à l'année précédente.

Métrique des ventes	2022 Performance
Équipe de vente totale	37 professionnels
Revenus de ventes directes	18,3 millions de dollars
Augmentation de la productivité des ventes	22%

Augmenter les efforts de marketing pour mettre en évidence les capacités de test Covid-19 et d'autres capacités de test de diagnostic

En 2022, les codiagnostics ont investi 2,7 millions de dollars dans des campagnes marketing, 65% se sont concentrés sur les capacités de test de diagnostic. Les ventes de kit de test Covid-19 de la société ont généré 12,5 millions de dollars de revenus.

• Investissement marketing: 2,7 millions de dollars
• Renus du kit de test Covid-19: 12,5 millions de dollars
• Focus marketing sur les tests de diagnostic: 65%

Développer des stratégies de tarification compétitives pour attirer plus de clients

Les codiagnostics ont mis en œuvre une stratégie de tarification à plusieurs niveaux, réduisant les prix du kit de test de 15% pour les achats en vrac. Cette approche a entraîné une augmentation de 28% des acquisitions de clients à grand volume en 2022.

Résultat de la stratégie de tarification	2022 Résultats
Réduction des prix pour les achats en vrac	15%
Augmentation des clients à grand volume	28%

Améliorer le support client et les offres de services techniques

La société a élargi son équipe de support client à 42 spécialistes techniques, réduisant le temps de réponse moyen de 24 à 12 heures. Les cotes de satisfaction des clients sont passées de 7,2 à 8,5 sur 10.

• Support technique Taille de l'équipe: 42 spécialistes
• Réduction du temps de réponse moyen: 12 heures
• Amélioration de l'évaluation de la satisfaction du client: 1,3 points

Mettre en œuvre des campagnes de marketing numérique ciblées pour sensibiliser la marque

Les efforts de marketing numérique en 2022 comprenaient un investissement de 1,5 million de dollars dans la publicité en ligne ciblée. La société a réalisé une augmentation de 42% du trafic de sites Web et une croissance de 35% de l'engagement des médias sociaux.

Métrique du marketing numérique	2022 Performance
Investissement en marketing numérique	1,5 million de dollars
Augmentation du trafic du site Web	42%
Croissance de l'engagement des médias sociaux	35%

Codiagnostics, Inc. (CODX) - Matrice Ansoff: développement du marché

Explorer les marchés internationaux dans les régions de demande de tests diagnostiques élevés

Les codiagnostiques ont élargi la présence internationale en 2022, avec une croissance des revenus de 36% des marchés internationaux. Les régions cibles clés comprennent l'Amérique latine, le Moyen-Orient et l'Asie du Sud-Est.

Région	Potentiel de marché	Taux de croissance des tests de diagnostic
l'Amérique latine	2,3 milliards de dollars	8.7%
Moyen-Orient	1,8 milliard de dollars	6.5%
Asie du Sud-Est	1,5 milliard de dollars	9.2%

Poursuivre des partenariats avec les systèmes de soins de santé

Les codiagnostics ont établi 12 nouveaux partenariats de systèmes de soins de santé en 2022, élargissant les capacités de test de diagnostic dans plusieurs pays.

• Brésil National Health System Valeur Contrat: 3,4 millions de dollars
• Partenariat du réseau de soins de santé des EAU: 2,7 millions de dollars
• Contrat d'infrastructure médicale de Singapour: 1,9 million de dollars

Développer des relations de distributeur stratégique

En 2022, les codiagnostiques ont signé des accords avec 18 nouveaux distributeurs internationaux sur les marchés mal desservis.

Région de distribution	Nombre de nouveaux distributeurs	Port du marché estimé
Afrique	5	42 millions de patients potentiels
Europe de l'Est	4	36 millions de patients potentiels
Asie du Sud-Est	9	68 millions de patients potentiels

Adapter les gammes de produits aux exigences réglementaires régionales

Les codiagnostics ont investi 2,3 millions de dollars dans la conformité réglementaire et l'adaptation des produits pour les marchés internationaux en 2022.

• Certification CE Mark pour les marchés européens
• Approbation Anvisa pour le marché brésilien
• Enregistrement SFDA pour les marchés du Moyen-Orient

Cibler les marchés émergents avec une infrastructure de santé croissante

Marché des tests de diagnostic du marché émergent prévu pour atteindre 12,4 milliards de dollars d'ici 2025, avec un taux de croissance annuel composé de 11,3%.

Marché émergent	Investissement d'infrastructure de soins de santé	Croissance du marché diagnostique
Inde	45 milliards de dollars	12.5%
Indonésie	22 milliards de dollars	9.8%
Nigeria	15 milliards de dollars	8.6%

Codiagnostics, Inc. (CODX) - Matrice ANSOFF: Développement de produits

Investissez dans la R&D pour les technologies de diagnostic moléculaire avancées

Les codiagnostics ont alloué 3,2 millions de dollars pour les frais de recherche et de développement en 2022. L'investissement en R&D de la société représentait 22,5% des revenus totaux au cours de l'exercice.

Métrique de R&D	Valeur 2022
Dépenses totales de R&D	3,2 millions de dollars
Pourcentage de revenus	22.5%

Développer des plateformes de tests multiplex pour la détection de maladies multiples

Les codiagnostiques ont développé 7 plates-formes de test multiplex capables de détecter simultanément plusieurs agents pathogènes, avec un taux de précision de détection de 98,6%.

• Plates-formes de tests multiplex totaux: 7
• Taux de précision de détection: 98,6%
• Pathogènes détectés: Covid-19, grippe, virus respiratoire syncytial

Développer le menu de test de diagnostic au-delà de Covid-19

L'entreprise a élargi son menu de test de diagnostic pour inclure 12 tests de maladies infectieuses différents en 2022, générant 4,7 millions de dollars de revenus de test non confortables.

Catégorie de test	Nombre de tests	Revenu
Tests de maladies infectieuses	12	4,7 millions de dollars

Créer des solutions de tests génétiques innovants

Codiagnostics a lancé 3 nouvelles solutions de tests génétiques en 2022, avec une pénétration du marché de 15% dans les segments de médecine de précision.

• Nouvelles solutions de tests génétiques: 3
• Pénétration du marché: 15%
• Segments cibles: oncologie, troubles génétiques rares

Améliorer les technologies de diagnostic avec l'IA et l'apprentissage automatique

La société a investi 1,8 million de dollars dans l'intégration de l'IA et de l'apprentissage automatique, améliorant la vitesse de traitement des tests de diagnostic de 37%.

Investissement d'IA	Amélioration de la vitesse de traitement
1,8 million de dollars	37%

Codiagnostics, Inc. (CODX) - Matrice Ansoff: diversification

Explorer les acquisitions potentielles dans les secteurs de la technologie de diagnostic complémentaire

Les codiagnostics ont déclaré un chiffre d'affaires total de 24,4 millions de dollars en 2022, en mettant l'accent sur l'expansion des capacités de technologie de diagnostic. Les frais de recherche et développement de l'entreprise se sont élevés à 5,6 millions de dollars au cours du même exercice.

Zones d'acquisition potentielles	Valeur marchande estimée	Potentiel stratégique
Diagnostic moléculaire	12,3 milliards de dollars	Haut
Plates-formes de tests génétiques	8,7 milliards de dollars	Moyen
Diagnostics des maladies infectieuses	6,5 milliards de dollars	Haut

Développer des solutions de diagnostic pour les marchés vétérinaires et agricoles

Le marché mondial du diagnostic vétérinaire était évalué à 4,2 milliards de dollars en 2022, avec un TCAC projeté de 8,3% à 2027.

• Potentiel du marché vétérinaire: 850 millions de dollars d'opportunité annuelle
• Marché des tests de diagnostic agricole: 1,2 milliard de dollars de croissance projetée
• Marché des tests de maladies zoonotiques: 620 millions de dollars de revenus potentiels

Étudier les opportunités dans la recherche génétique et la médecine personnalisée

Le marché mondial de la médecine personnalisée a atteint 493,7 milliards de dollars en 2022, avec une croissance attendue à 817,6 milliards de dollars d'ici 2027.

Segment de recherche génétique	Taille du marché	Taux de croissance
Dépistage génétique	22,5 milliards de dollars	11.2%
Médecine de précision	67,3 milliards de dollars	13.5%

Créer des partenariats stratégiques en biotechnologie et recherche pharmaceutique

Les codiagnostics ont signalé 3 partenariats de recherche stratégique en 2022, avec un financement potentiel de recherche en collaboration de 3,2 millions de dollars.

• Potentiel de collaboration de recherche pharmaceutique: 5,6 millions de dollars
• Opportunités de partenariat en biotechnologie: 4,3 millions de dollars
• Soutien diagnostique des essais cliniques: 2,1 millions de dollars de revenus potentiels

Se développer dans les plates-formes de santé numériques pour la gestion et l'analyse des données de diagnostic

Le marché mondial de la santé numérique était évalué à 211 milliards de dollars en 2022, avec un segment de gestion des données de diagnostic estimé à 42,5 milliards de dollars.

Segment de la santé numérique	Valeur marchande	Projection de croissance
Plates-formes de données de diagnostic	42,5 milliards de dollars	15.3%
Analyse diagnostique dirigée par l'IA	18,7 milliards de dollars	22.6%

Co-Diagnostics, Inc. (CODX) - Ansoff Matrix: Market Penetration

You're looking at the core business-selling what Co-Diagnostics, Inc. (CODX) already has, to the customers it already knows, primarily in the US clinical lab space. The numbers for 2025 show a significant shift in revenue composition, moving away from grant timing toward product sales, which is the goal of market penetration, even if the top line is currently challenged.

For the third quarter ending September 30, 2025, Co-Diagnostics, Inc. (CODX) reported revenue of \$0.1 million. This compares to the trailing twelve-month (TTM) revenue as of September 30, 2025, which stood at \$508K. The estimated full-year 2025 revenue projection was \$523,260. The focus on increasing utilization means driving repeat purchases and deeper adoption of the Co-Dx PCR platform within the existing customer base.

To capture greater market share, the strategy hinges on pricing relevance, which is a precursor to volume-based discounts. For instance, the target pricing for the Co-Dx PCR Pro instrument is set between \$300-\$500 in developed markets, with test cups priced at \$15-\$20 in those same markets. The actual investment in expanding the commercial footprint is reflected in the Q2 2025 GAAP sales and marketing expense, which was \$0.6 million.

Aggressively cross-selling existing tests, like the enhanced COVID-19 test, is key. The enhanced COVID-19 test is planned as the first of four infectious disease PCR test panels to be submitted for regulatory clearance following clinical evaluations. While specific sales figures for Zika, Dengue, and Chikungunya (ZDC) tests aren't broken out, the company is actively pursuing international expansion, notably through the CoMira joint venture in Saudi Arabia and 18 MENA nations, which serves as a commercial channel for endemic region tests.

Here's a quick look at the financial context for Co-Diagnostics, Inc. (CODX) through the first three quarters of 2025:

Metric	Q2 2025	Q3 2025	Full Year 2024
Revenue (GAAP)	\$0.2 million	\$0.1 million	\$3.9 million
Operating Expenses	\$8.2 million	\$7.1 million	\$43.0 million
Net Loss	\$7.7 million	\$5.9 million	\$37.6 million
Cash, Cash Equivalents, and Marketable Securities (End of Period)	\$13.4 million (as of June 30, 2025)	\$11.4 million (as of September 30, 2025)	\$29.7 million (as of December 31, 2024)

The drive to increase utilization involves ensuring the platform is ready for high-volume use. The company is preparing to initiate clinical evaluations for all tests in the Co-Dx PCR platform pipeline before the end of 2025. This readiness is a prerequisite for any successful volume-based strategy.

The actions supporting market penetration include:

• Focus on completing clinical evaluations for the Co-Dx PCR platform pipeline.
• Training clinical evaluation sites for the enhanced COVID-19 test.
• Reducing operating expenses, which fell to approximately \$7.1 million in Q3 2025, a decrease of 32.6% year-over-year.
• Advancing the regulatory strategy, with the enhanced COVID-19 test targeted as the first submission.
• Leveraging the CoMira JV to expand commercial reach into the Middle East, which supports sales in endemic regions.

If onboarding takes 14+ days, churn risk rises.

Finance: draft 13-week cash view by Friday.

Co-Diagnostics, Inc. (CODX) - Ansoff Matrix: Market Development

You're looking at how Co-Diagnostics, Inc. (CODX) is pushing its existing PCR technology into new geographic and application spaces. This Market Development strategy hinges on regulatory progress and forging strong local alliances, especially since the core Co-Dx PCR platform is still under review and not yet commercially available, with commercialization anticipated in 2026.

The financial context for this expansion is tight, reflecting ongoing development costs. For the third quarter ending September 30, 2025, revenue was reported at $0.1M, down from $0.6M in Q3 2024, largely due to grant revenue timing. The net loss for Q3 2025 was $5.9M, and cash, cash equivalents, and marketable securities stood at $11.4M as of that date. Operating expenses saw a significant year-over-year reduction of 32.6% to approximately $7.1M in Q3 2025.

Metric	Q3 2025 Value	Comparison/Context
Revenue (Q3 2025)	$0.1M	Down from $0.6M in Q3 2024
Net Loss (Q3 2025)	$5.9M	Loss per share of $0.16
Cash & Marketable Securities (Sep 30, 2025)	$11.4M	Followed two Registered Direct Offerings totaling ~$10.8M in-quarter
Operating Expenses (Q3 2025)	~$7.1M	Decreased by 32.6% year-over-year
New Test Panel Submissions Planned	Four	Enhanced COVID-19 test is planned as the first submission post-clinical evaluation

To secure entry into new international markets, securing regulatory approvals is key. The company remains on track to reach its 2025 development and regulatory milestones. The enhanced COVID-19 test is slated to be the first of four infectious disease PCR test panels submitted for regulatory clearance following the completion of clinical evaluations.

Market development efforts are heavily focused on the Middle East and North Africa (MENA) region. Co-Diagnostics, Inc. signed a strategic Memorandum of Understanding (MOU) in September 2025 to explore a Joint Venture (JV) in the Kingdom of Saudi Arabia (KSA) with a regional partner. This JV, CoMira Diagnostics, is intended to handle the development, manufacturing, and sale of Co-Dx intellectual property across KSA and 18 MENA nations.

This regional focus is strategic, as KSA has historically been one of the largest international markets for Co-Diagnostics, Inc.'s Logix Smart® tests. The JV's mission is anticipated to align with KSA's Vision 2030, potentially making it eligible for applicable KSA government incentives, which directly addresses focusing on government tenders.

For broader international reach, Co-Diagnostics, Inc. is actively engaging in networking opportunities. The executive leadership team hosted a booth at the Global Health Exhibition 2025 in Riyadh, KSA, in October 2025, which was expected to host over 160,000 healthcare professionals. Earlier in July 2025, the company hosted a booth at WHX Kuala Lumpur, the leading healthcare exhibition in Southeast Asia, targeting attendees from over 54 countries.

The push into non-clinical markets is supported by the existing technology base. The company explicitly states it uses its proprietary technology to identify genetic markers for applications other than infectious disease. Furthermore, a new artificial intelligence (AI) business unit was announced to integrate AI applications into the Co-Dx™ Primer Ai™ platform, which supports internal data workflow and Co-Primers design and optimization.

Adapting the platform for point-of-care (PoC) settings is a major component of market development, especially for rural areas. Co-Diagnostics, Inc. initiated clinical evaluations in November 2025 for an Upper Respiratory Multiplex Point-of-Care Test to support a U.S. FDA submission. This follows the development of a proprietary sample preparation instrument designed to streamline the workflow for the PoC Mycobacterium Tuberculosis (MTB) Test.

Key Market Development Activities in 2025:

• Initiated clinical evaluations for the Upper Respiratory Multiplex Point-of-Care Test in November 2025.
• Signed MOU in September 2025 for KSA JV to cover 18 MENA nations.
• Developed a proprietary sample preparation instrument for the PoC Mycobacterium Tuberculosis (MTB) Test.
• Attended WHX Kuala Lumpur in July 2025, targeting an audience from over 54 countries.
• Formed an AI business unit to enhance the Co-Dx™ Primer Ai™ platform.

Finance: draft 13-week cash view by Friday.

Co-Diagnostics, Inc. (CODX) - Ansoff Matrix: Product Development

You're looking at the tangible steps Co-Diagnostics, Inc. is taking to expand its product offerings, which is the core of the Product Development quadrant in the Ansoff Matrix.

The company is actively advancing its pipeline, with a clear focus on leveraging its Co-Dx PCR platform for new indications and more comprehensive panels. For instance, clinical evaluations have begun for the Co-Dx PCR Flu A/B, COVID-19, RSV Test Kit on the compact Co-Dx PCR Pro instrument to support a United States Food and Drug Administration (FDA) 510(k) submission. This multiplex RT-PCR test is designed for the simultaneous detection and differentiation of influenza A, influenza B, COVID-19, and RSV at the point-of-care.

Co-Diagnostics, Inc. also plans to initiate clinical evaluations for its tuberculosis (MTB) and Human Papillomavirus (HPV) assays before the end of 2025. The HPV assay is notable as it can detect eight high-risk subtypes from a single swab, with initial regulatory focus in India through the CoSara Diagnostics joint venture.

The financial commitment to this development is reflected in the reported Research and Development Expenses. For the third quarter of 2025, R&D expenses totaled $4.5 million, a decrease from $4.9 million in the third quarter of 2024. This cost management is part of a broader operational efficiency drive, as total operating expenses for Q3 2025 were approximately $7.1 million, down 32.6% year-over-year from $10.6 million in Q3 2024.

Here's a quick look at the pipeline progress and associated financial data as of the third quarter of 2025:

Product Development Initiative	Status/Metric	Relevant Financial Data (Q3 2025)
Multiplex Respiratory Test (Flu A/B, COVID-19, RSV)	Clinical evaluations initiated for FDA 510(k) support.	R&D Expense: $4.5 million.
Tuberculosis (MTB) and HPV Assays	Clinical studies for MTB planned in India and South Africa in H2 2025 for regulatory submissions. HPV assay detects eight high-risk subtypes.	Net Loss: $5.9 million (loss of $0.16 per share).
Co-Dx PCR Platform Commercialization	Platform remains under regulatory review and is not available for sale. Instrument pricing targeted at $300-$500.	Cash, cash equivalents, and marketable securities: $11.4 million as of September 30, 2025.

To simplify lab workflow, Co-Diagnostics, Inc. developed a proprietary sample preparation instrument specifically for the point-of-care (PoC) Co-Dx PCR Mycobacterium Tuberculosis (MTB) Test. The company also announced the formation of a new artificial intelligence (AI) business unit to integrate AI applications into the Co-Dx™ Primer Ai™ platform, aiming to accelerate assay design and automate interpretation.

The company is also securing capital to support these efforts. Subsequent to the third quarter, Co-Diagnostics, Inc. closed a Registered Direct Offering (RDO) for approximately $7.0 million, following a $3.8 million RDO closed in-quarter, totaling gross proceeds of approximately $10.8 million from these two offerings. The Q3 2025 revenue was $0.1 million, all derived from product sales, compared to $0.6 million in Q3 2024, which included approximately $0.4 million in grant revenue.

The product development focus can be summarized by the planned advancements for the Co-Dx PCR platform:

• Initiate clinical evaluations for the Flu A/B, COVID-19, RSV multiplex test.
• Plan clinical evaluations for MTB and HPV assays before year-end 2025.
• Developed a proprietary sample preparation instrument for the MTB PoC Test.
• Launched an AI business unit to enhance the Co-Dx™ Primer Ai™ platform.
• Instrument pricing is aimed at $300-$500 per unit.

Co-Diagnostics, Inc. (CODX) - Ansoff Matrix: Diversification

You're looking at Co-Diagnostics, Inc. (CODX) moving outside its core infectious disease testing base. Diversification here means using that patented Co-Dx technology in entirely new revenue streams. It's a necessary pivot when quarterly revenue, like the $0.15 million reported for Q3 2025, is lean compared to operating expenses, such as the $8.6 million operating loss in Q1 2025.

The company's current financial footing, with cash, cash equivalents, and marketable securities at $11.4 million as of September 30, 2025, provides a runway, but new avenues are key to reversing the net loss trend, which was $7.7 million in Q2 2025. The market expects some improvement, forecasting the EPS to move from ($1.22) to ($1.17) per share next year.

Here's how the diversification strategy maps against market opportunity:

• Acquire a complementary business in the life science tools sector, moving beyond pure diagnostics.
• Enter the therapeutic drug monitoring market by developing new assays and services.
• Establish a direct-to-consumer (DTC) testing service for wellness or genetic screening in a new geography.
• Partner with a pharmaceutical company to develop companion diagnostics for new drug candidates.
• License the Co-Diagnostics, Inc. Co-Dx technology for non-diagnostic industrial applications.

Entering the Therapeutic Drug Monitoring (TDM) Market

Moving into TDM means targeting a market that needs precise, repeatable assays, which aligns well with Co-Diagnostics, Inc.'s core competency. The TDM market is substantial and growing. One estimate places the global TDM market size at USD 2.43 billion in 2025, with a projection to reach USD 5.28 billion by 2033, showing a compound annual growth rate (CAGR) of 10.2% during the 2025-2033 period. Another projection sees the market at USD 1.3 billion in 2025, growing at a CAGR of 7.7% through 2035.

North America currently holds a leading position, securing over 41.4% of the market revenue in 2024. However, the Asia-Pacific region is expected to be the fastest-growing, with a projected CAGR of 10.5% between 2025 and 2032.

Direct-to-Consumer (DTC) Testing Expansion

Establishing a DTC testing service, perhaps focusing on wellness or genetic screening in a new geography, taps into a high-growth consumer segment. The global DTC Genetic Testing Market size is estimated at USD 2.57 billion in 2025. This segment is projected to expand significantly, reaching USD 9.20 billion by 2033, reflecting a CAGR of 17.30% over the 2025-2033 forecast period. Another source estimates the market will grow from USD 4.5 billion in 2025 to USD 13 billion by 2034, at a CAGR of 12.4%.

North America dominates this space, accounting for approximately 62% of the global market share in 2024. For Co-Diagnostics, Inc., expanding into a new geography like the Asia Pacific region, which is estimated to grow at the highest CAGR during the 2025-2030 period, presents a clear path for new customer acquisition.

Industrial Licensing and Partnerships

Licensing the Co-Dx technology for non-diagnostic industrial applications or partnering for companion diagnostics leverages existing intellectual property without requiring full-scale commercialization infrastructure in those new fields. The broader Molecular Diagnostics Market, which sets the context for licensing opportunities, is valued at an estimated USD 19.48 billion in 2025, growing to USD 30.74 billion by 2030 at a CAGR of 9.6%. The landscape of deal-making is active; one report details 759 molecular diagnostics collaboration and licensing deals announced since 2016.

The potential for companion diagnostics is tied to the overall growth in drug development, where precision is paramount. The existing focus on developing 4 main tests for the Co-Dx PCR platform, including enhanced COVID-19, Upper Respiratory Multiplex, HPV multiplex, and Tuberculosis tests, shows the internal capacity for assay development that could be adapted.

Here's a snapshot comparing the potential market scale for two diversification targets:

Market Segment	Estimated Market Value (2025)	Projected CAGR (Approximate)	North America Market Share (Latest Data)
Therapeutic Drug Monitoring (TDM)	USD 2.43 billion	10.2% (to 2033)	Over 41.4% (in 2024)
Direct-to-Consumer (DTC) Genetic Testing	USD 2.57 billion	17.30% (to 2033)	Approximately 62% (in 2024)

The recent establishment of the AI business unit, led by the Chief Technology & AI Officer, also suggests an internal capability to support technology licensing or the development of advanced TDM algorithms.

Finance: review capital allocation for potential acquisition targets by end of Q1 2026.